Condition: Recurrent Ovarian Cancer · Signal Transduction Pathway Deregulation · Therapy-Associated Cancer · Sponsor: Gynaecologisch Oncologisch Centrum Zuid
The purpose of this prospective, parallel-group, cohort study is to implement phenotype-guided targeted therapy based on functional signal transduction pathway (STP) activity in recurrent ovarian cancer patients using a novel mRNA-based assay. Existing targeted drugs with tolerable toxicity profiles are used to investigate the therapeutic value beyond their approved indication, which are deemed beneficial in the select group of patients with a relevant predominantly active functional STP, in order to improve survival and maintain quality of life.
This description comes directly from the study's public registry record.
Jurgen M Piek, MD, PhD · +31(0)40 239 91 11 · jurgen.piek@catharinaziekenhuis.nl
Ruud Bekkers, MD, PhD · +31(0)40 239 91 11 · ruud.bekkers@catharinaziekenhuis.nl
Always discuss trial participation with your own doctor first.
| Radboudumc | Nijmegen, Gelderland, Netherlands | Not Yet Recruiting |
| Catharina Ziekenhuis | Eindhoven, North Brabant, Netherlands | Recruiting |
| Amphia Hospital | Breda, Netherlands | Not Yet Recruiting |
| Maastricht UMC+ | Maastricht, Netherlands | Not Yet Recruiting |
| Erasmus MC | Rotterdam, Netherlands | Not Yet Recruiting |
| Elisabeth-Tweesteden Hospital | Tilburg, Netherlands | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03458221